A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics

[1]  P. Park,et al.  Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Y. Yatabe,et al.  Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  G. Getz,et al.  RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer , 2015, Nature Communications.

[4]  P. Dartevelle,et al.  Small-Cell Carcinoma in the Setting of Pulmonary Adenocarcinoma: New Insights in the Era of Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  A. Nicholson,et al.  Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. , 2013, Lung cancer.

[6]  E. Brambilla,et al.  Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: a retrospective study of 300 patients. , 2012, Lung cancer.

[7]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.